ENA Respiratory, a clinical-stage pharmaceutical startup developing host defence enhancers for the prevention of complications associated with respiratory viral infections in at-risk populations, has been awarded AUD $2,980,000 in funding from Australia’s Biointelect Venturer as part of its inaugural funding round.
